SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-154587"
 

Search: onr:"swepub:oai:DiVA.org:liu-154587" > Validation of the m...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Roncolato, Felicia TNHMRC Clinical Trials Centre, University of Sydney, Australia; Macarthur Cancer Therapy Centre, NSW, Australia; Australia New Zealand Gynaecological Oncology Group (ANZGOG), Australia (author)

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) : Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)

  • Article/chapterEnglish2018

Publisher, publication year, extent ...

  • Academic Press,2018
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-154587
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-154587URI
  • https://doi.org/10.1016/j.ygyno.2017.10.019DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:137464649URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • BACKGROUND: Modified Glasgow Prognostic Score (mGPS) is predictive of survival in many advanced cancers, but has not been evaluated in recurrent ovarian cancer (ROC). The aim was to determine validity of mGPS in ROC, investigate its associations with health related quality of life (HRQL) and ECOG performance status (PS).METHODS: mGPS is based on serum C reactive protein (CRP) and albumin, with scores ranging from 0 (least) to 2 (most). HRQL was measured with EORTC QLQ C-30 and OV-28. χ2 tests for trend were used to examine the relationship between HRQL, PS and mGPS. Cox proportional hazards regression was used to assess associations between mGPS, HRQL, clinicopathological factors, and overall survival (OS).RESULTS: Inflammatory markers were available in 516 of 948 patients in GCIG SBS. 200(39%) had potentially platinum sensitive ROC with ≥3 lines of chemotherapy, 316(61%) had platinum resistant ROC. 282(55%), 123(24%), 111(22%) had mGPS of 0, 1, 2, respectively. Median OS (months) was 18.1, 9.6, and 6.6 for mGPS 0, 1, and 2 respectively. mGPS was an independent predictor of OS after adjusting for PS and platinum sensitivity (p<0.001). mGPS remained a predictor of OS after adjusting for physical function, role function, global health status, abdominal/GI symptoms, and multiple clinicopathologic factors (p=0.02). Worse PS and higher mGPS were associated with poorer HRQL (p<0.001). Higher mGPS was associated with worse HRQL, independent of PS.CONCLUSION: The mGPS is an independent predictor of OS in ROC after adjusting for HRQL and clinicopathological factors. Higher mGPS is associated with worse HRQL independent of PS. mGPS is simple, inexpensive and may be suitable for clinical practice, clinical trial patient selection and stratification.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Berton-Rigaud, DominiqueICO Centre René Gauducheau, Saint Herblain, France (author)
  • O'Connell, RachelNHMRC Clinical Trials Centre, University of Sydney, Australia (author)
  • Lanceley, AnneUniversity College London, United Kingdom (author)
  • Sehouli, JalidCharite Berlin, Germany (author)
  • Buizen, LukeNHMRC Clinical Trials Centre, University of Sydney, Australia (author)
  • Okamoto, AikouJikei University School of Medicine, Japan (author)
  • Aotani, ErikoKitasato Academic Research Organization, Japan (author)
  • Lorusso, DomenicaMITO, Rome, Italy (author)
  • Donnellan, PaulGalway University Hospital, Ireland; All-Ireland Oncology Research Group (ICORG), Ireland (author)
  • Oza, AmitPrincess Margaret Hospital, Canada (author)
  • Åvall-Lundqvist, Elisabeth,1957-Linköpings universitet,Avdelningen för Kirurgi, Ortopedi och Onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US,Karolinska Institutet, Stockholm, Sweden(Swepub:liu)eliav51 (author)
  • Berek, JonathanStanford Women's Cancer Center, USA (author)
  • Hilpert, FelixKlinik fur Gynakologie und Geburtshilfe, UKSH, Germany (author)
  • Ledermann, Jonathan ACRUK and UCL Cancer Trials Centre, NCRI UK, United Kingdom (author)
  • Kaminsky, Marie ChristineICL Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France (author)
  • Stockler, Martin RNHMRC Clinical Trials Centre, University of Sydney, Australia (author)
  • King, Madeleine TPsycho-oncology Research Group (PoCoG), School of Psychology, Central Clinical School, Sydney Medical School, University of Sydney, Australia (author)
  • Friedlander, MichaelAustralia New Zealand Gynaecological Oncology Group (ANZGOG), Australia; Prince of Wales Hospital, Sydney, Australia (author)
  • NHMRC Clinical Trials Centre, University of Sydney, Australia; Macarthur Cancer Therapy Centre, NSW, Australia; Australia New Zealand Gynaecological Oncology Group (ANZGOG), AustraliaICO Centre René Gauducheau, Saint Herblain, France (creator_code:org_t)

Related titles

  • In:Gynecologic Oncology: Academic Press148:1, s. 36-410090-82581095-6859

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view